Losartan as Anti-inflammatory Therapy to Augment F508del Cystic Fibrosis Transmembrane (CFTR) Recovery
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Losartan (Primary)
- Indications Cystic fibrosis; Inflammation
- Focus Proof of concept; Therapeutic Use
- 03 Jan 2020 Status changed from recruiting to discontinued.
- 02 Aug 2019 Planned End Date changed from 10 Aug 2020 to 30 Jun 2020.
- 02 Aug 2019 Planned primary completion date changed from 10 Aug 2019 to 31 Dec 2019.